Palazón Carrión, N., Martín García-Sancho, A., Nogales-Fernández, E., Jiménez Cortegana, C., Carnicero-González, F., Ríos Herranz, E., . . . Cruz Merino, L. d. l. (2022). Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Citação norma ChicagoPalazón Carrión, Natalia, Alejandro Martín García-Sancho, Esteban Nogales-Fernández, Carlos Jiménez Cortegana, Fernando Carnicero-González, Eduardo Ríos Herranz, Víctor Sánchez Margalet, Antonio Rueda Domínguez, y Luis de la Cruz Merino. Lenalidomide Plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. 2022.
Citação norma MLAPalazón Carrión, Natalia, et al. Lenalidomide Plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. 2022.